All In Biotech

Drug Trial Radar · NCT06450197

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients With Moderate to Severe Crohn's Disease

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

120

Actual

Start

Aug 28, 2024

Primary completion

Apr 30, 2026

Study completion May 14, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.

Conditions

  • Moderate to Severe Crohn's Disease

Interventions

  • AZD7798Drug

    AZD7798

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CDAI remissionTime frame: Week 12

Locations

116 sites in 26 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Escondido, California

  • Research Site

    La Jolla, California

  • Research Site

    Orlando, Florida

  • Research Site

    Idaho Falls, Idaho

  • Research Site

    Kansas City, Kansas

  • Research Site

    Clinton Township, Michigan

  • Research Site

    St Louis, Missouri

  • Research Site

    Asheville, North Carolina

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Uniontown, Pennsylvania

  • Research Site

    Garland, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Ciudad Autonoma de Bs As, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    San Miguel de Tucumán, Argentina

  • Research Site

    Adelaide, Australia

  • Research Site

    Box Hill, Australia

  • Research Site

    Fitzroy, Australia

  • Research Site

    Melbourne, Australia

  • Research Site

    Wollongong, Australia

  • Research Site

    Leuven, Belgium

  • Research Site

    Campinas, Brazil

  • Research Site

    Jaú, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Santo André, Brazil

  • Research Site

    São José do Rio Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Gorna Oryahovitsa, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Lethbridge, Alberta, Canada

  • Research Site

    Santiago, Chile

  • Research Site

    Santiago, Chile

  • Research Site

    Santiago, Chile

  • Research Site

    Viña del Mar, Chile

  • Research Site

    Beijing, China

  • Research Site

    Chengdu, China

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.